arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Protagonist Therapeutics, Inc

PTGX
$138.66 ▼ -6.49 (-4.47%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
47 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Protagonist Therapeutics, Inc faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $9.1B
Dividend Yield
Revenue Growth 3749.2%
Op. Margin 74.4%
ROIC 18.6%
FCF / Share $3.32
Trailing P/E 56.1x
Price / Book 10.7x
FCF Yield 2.4%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

47-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$213.47M
↑ +3749.2%
Net Income Profit after all expenses
$162.85M
↑ +4204.8%
Operating Margin Operating profit as % of sales
74.4%
↑ +1249.2% 0th
FCF / Share Free cash flow per share
$3.32
↑ +539.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
34
Returns
27
Cash Quality
14

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 13 years · 47 quarters